Effects of pioglitazone and retinoic acid in a rotenone model of Parkinson's disease

Brain Research Bulletin

Volumn 85, Issue 6, 2011, Pages 380-384

  Ulusoy, Gokhan K ^a   Celik, Turgay ^a   Kayir, Hakan ^a   Gürsoy, Murat ^b   Isik, Ahmet T ^a   Uzbay, Tayfun I ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b ULUDAG UNIVERSITY   (Turkey)

Author keywords

Parkinson's disease; Pioglitazone; Rat(s); Retinoic acid; Rotenone

Indexed keywords

DOPAMINE; PIOGLITAZONE; RETINOIC ACID; ROTENONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DRUG EFFECT; HIPPOCAMPUS; HYPOTHALAMUS; LOCOMOTION; MALE; NEUROCHEMISTRY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; DISEASE MODELS, ANIMAL; HYPOGLYCEMIC AGENTS; MALE; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE, SECONDARY; RATS; RATS, WISTAR; ROTENONE; THIAZOLIDINEDIONES; TRETINOIN;

EID: 79960171961     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2011.05.001     Document Type: Article

References (39)

1. Ahlemeyer B., Hühne R., Krieglstein J. Retinoic acid potentiated the protective effect of NGF against staurosporine-induced apoptosis in cultured chick neurons by increasing the trkA protein expression. J. Neurosci. Res. 2000, 60:767-778.
2. Alam M., Schmidt W.J. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav. Brain Res. 2002, 136:31-324.
3. Andersen J.K. Oxidative stress in neurodegeneration: cause or consequence?. Nat. Med. 2004, 10(Suppl.):S18-S25.
4. Barbiero J.K., Santiago R.M., Lima M.M., Ariza D., Morais L.H., Andreatini R., Vital M.A. Acute but not chronic administration of pioglitazone promoted behavioral and neurochemical protective effects in the MPTP model of Parkinson's disease. Behav. Brain Res. 2011, 216:186-192.
5. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 2000, 3:1301-1316.
6. Bindoff L.A., Birch-Martin M., Cartlidge N.E.F., Parker W.D., Turnbull D.M. Mitochondrial function in Parkinson's disease. Lancet 1989, 2:49.
7. Bordet R., Ouk T., Petrault O., Gelé P., Gautier S., Laprais M., Deplanque D., Duriez P., Staels B. PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem. Soc. Trans. 2006, 34(Pt 6):1341-1346.
8. Breidert T., Callebert J., Heneka M.T., Landreth G., Launay J.M., Hirsch E.C. Protective action of the peroxime proliferators-activated receptor-γ agonist pioglitazone in a mouse model of Parkinson's disease. J. Neurochem. 2002, 82:615-624.
9. Cannon J.R., Tapias V., Na H.M., Honick A.S., Drolet R.E., Greenamyre J.T. A highly reproducible rotenone model of Parkinson's disease. Neurobiol. Dis. 2009, 34:279-290.
10. Dehmer T., Heneka M.T., Sastre M., Dichgans J., Schulz J.B. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J. Neurochem. 2004, 88:494-501.
11. Ernster L., Dallner G., Azzone G.F. Differential effects of rotenone and amytal on mitochondrial electron and energy transfer. J. Biol. Chem. 1963, 238:1124-1131.
12. Ferrante R.J., Schulz J.B., Kowall N.W., Beal M.F. Systemic administration of rotenone produces selective damage in the striatum and globus pallidum, but not in the substantia nigra. Brain Res. 1997, 753:157-162.
13. Gandhi S, Wood N.W. Molecular pathogenesis of Parkinson's disease. Hum. Mol. Genet. 2005, 14:2749-2755.
14. Gorell J.M., Johnson C.C., Rybicki B.A., Peterson E.L., Richardson R.J. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 1998, 50:1346-1350.
15. Gürsoy M., Büyükuysal R.L. Resveratrol protects rat striatal slices against anoxia-induced dopamine release. Neurochem. Res. 2008, 33:1838-1844.
16. Höglinger G.U., Féger J., Prigent A., Michel P.P., Parain K., Champy P., Ruberg M., Oertel W.H., Hirsch E.C. Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J. Neurochem. 2003, 84:491-502.
17. Katsuki H., Kurimoto E., Takemori S., Kurauchi Y., Hisatsune A., Isohama Y., Izumi Y., Kume T., Shudo K., Akaike A. Retinoic acid receptor stimulation protects midbrain dopaminergic neurons from inflammatory degeneration via BDNF-mediated signaling. J. Neurochem. 2009, 110:707-718.
18. Kieburtz K. Designing neuroprotection trials in Parkinson's disease. Ann. Neurol. 2003, 53(Suppl. 3):S100-S109.
19. Kumar P., Kaundal R.K., More S., Sharma S.S. Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease. Behav. Brain Res. 2009, 197:398-403.
20. Lee H.P., Casadesus G., Zhu X., Lee H.G., Perry G., Smith M.A., Gustaw-Rothenberg K., Lerner A. All-trans retinoic acid as a novel therapeutic strategy for Alzheimer's disease. Expert Rev. Neurother. 2009, 9:1615-1621.
21. Lin C.H., Huang J.Y., Ching C.H., Chuang J.I. Melatonin reduces the neuronal loss, downregulation of dopamine transporter, and upregulation of D2 receptor in rotenone-induced parkinsonian rats. J. Pineal Res. 2008, 44:205-213.
22. Lowry O.H., Rosenbrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
23. Moraes L.A., Piqueras L., Bishop-Bailey D. Peoxisome proliferator-activated receptors and inflammation. Pharmacol. Ther. 2006, 110:371-385.
24. Panov A., Dikalov S., Shalbuyeva N., Taylor G., Sherer T., Greenamyre J.T. Rotenone model of Parkinson disease: multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication. J. Biol. Chem. 2005, 280:42026-42035.
25. Perier C., Bové J., Vila M., Przedborski S. The rotenone model of Parkinson's disease. Trends Neurosci. 2003, 26:345-346.
26. Quinn L.P., Crook B., Hows M.E., Vidgeon-Hart M., Chapman H., Upton N., Medhurst A.D., Virley D.J. The PPARγ agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxydase B. Br. J. Pharmacol. 2008, 154:226-233.
27. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 1990, 54:823-827.
28. Schapira A.H. Etiology of Parkinson's disease. Neurology 2006, 66(Suppl. 4):S10-S23.
29. Schuler F., Casida J.E. Functional coupling of PSST and ND1 subunits in NADH: ubiquinone oxireductase established by photoaffinity labeling. Biochim. Biophys. Acta 2001, 1506:79-87.
30. Shah P., Mudaliar S. Pioglitazone: side effect and safety profile. Expert Opin. Drug Saf. 2010, 9:347-354.
31. Sherer T.B., Betarbet R., Testa C.M., Seo B.B., Richardson J.R., Kim J.H., Miller G.W., Yagi T., Matsuno-Yagi A., Greenamyre J.T. Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 2003, 23:10756-10764.
32. Sherer T.B., Kim J.H., Betarbet R., Greenamyre J.T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp. Neurol. 2003, 179:9-16.
33. Sherer T.B., Betarbet R., Greenamyre J.T. Animal Models of Movement Disorders 2005, 161-172. Elsevier Academic Press, London. M. LeDoux (Ed.).
34. Shinozaki Y., Sato Y., Koizumi S., Ohno Y., Nagao T., Inoue K. Retinoic acids acting through retinoid receptors protect hippocampal neurons from oxygen-glucose deprivation-mediated cell death by inhibition of c-jun-N-terminal kinase and p38 mitogen-activated protein kinase. Neuroscience 2007, 147:153-163.
35. Sian J., Dexter D.T., Lees A.J., Daniel S., Agid Y., Javoy-Agid F., Jenner P., Marsden C.D. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 1994, 36:348-355.
36. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
37. Strecker K., Schwarz J. Parkinson's disease: emerging pharmacotherapy. Expert Opin. Emerg. Drugs 2008, 13:573-591.
38. Wooten G.F. Movement Disorders: Neurologic Principles and Practise 1997, 153-160. McGraw Hill, New York. R.L. Watts, W.C. Koller (Eds.).
39. Yang Y., Liu X., Long Y., Wang F., Ding J.H., Liu S.Y., Sun Y.H., Yao H.H., Wang H., Wu J., Hu G. Systematic administration of iptakalim, an ATP-sensitive potassium channel opener, prevents rotenone-induced motor and neurochemical alterations in rats. J. Neurosci. Res. 2005, 80:442-449.